Navellier & Associates’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q2 | – | Sell |
-5,931
| Closed | -$269K | – | 259 |
|
|
2020
Q1 | $269K | Hold |
5,931
| – | – | 0.06% | 187 |
|
|
2019
Q4 | $386K | Sell |
5,931
-713
| -11% | -$46.4K | 0.06% | 210 |
|
|
2019
Q3 | $413K | Buy |
6,644
+64
| +1% | +$3.98K | 0.07% | 192 |
|
|
2019
Q2 | $469K | Hold |
6,580
| – | – | 0.07% | 184 |
|
|
2019
Q1 | $516K | Sell |
6,580
-32
| -0.5% | -$2.51K | 0.08% | 160 |
|
|
2018
Q4 | $560K | Sell |
6,612
-12,930
| -66% | -$1.1M | 0.1% | 136 |
|
|
2018
Q3 | $3.35M | Buy |
19,542
+3,754
| +24% | +$643K | 0.43% | 65 |
|
|
2018
Q2 | $2.04M | Buy |
15,788
+1,295
| +9% | +$167K | 0.28% | 109 |
|
|
2018
Q1 | $1.49M | Buy |
14,493
+7,857
| +118% | +$809K | 0.23% | 119 |
|
|
2017
Q4 | $567K | Buy |
+6,636
| New | +$567K | 0.11% | 172 |
|
|
2017
Q3 | – | Sell |
-6,636
| Closed | -$503K | – | 278 |
|
|
2017
Q2 | $503K | Sell |
6,636
-1,066
| -14% | -$80.8K | 0.08% | 181 |
|
|
2017
Q1 | $509K | Sell |
7,702
-10,672
| -58% | -$705K | 0.07% | 186 |
|
|
2016
Q4 | $1.17M | Buy |
18,374
+2,298
| +14% | +$146K | 0.19% | 128 |
|
|
2016
Q3 | $1.02M | Buy |
16,076
+8,010
| +99% | +$510K | 0.15% | 128 |
|
|
2016
Q2 | $600K | Sell |
8,066
-1,164
| -13% | -$86.6K | 0.09% | 128 |
|
|
2016
Q1 | $617K | Sell |
9,230
-6,202
| -40% | -$415K | 0.08% | 116 |
|
|
2015
Q4 | $1.04M | Buy |
15,432
+8,613
| +126% | +$583K | 0.11% | 82 |
|
|
2015
Q3 | $364K | Buy |
+6,819
| New | +$364K | 0.04% | 199 |
|
|
2014
Q3 | – | Sell |
-17,351
| Closed | -$674K | – | 345 |
|
|
2014
Q2 | $674K | Sell |
17,351
-8,563
| -33% | -$333K | 0.03% | 147 |
|
|
2014
Q1 | $1.09M | Sell |
25,914
-13,860
| -35% | -$581K | 0.05% | 91 |
|
|
2013
Q4 | $1.31M | Buy |
+39,774
| New | +$1.31M | 0.06% | 81 |
|